Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

😂👍

Spaß Jungs Langfristig bin ich definitiv überzeugt

Haha Wenn ich in Zukunft mal bisschen Geld loswerden will, einfach in bico investieren

Auf bico ist sozusagen verlass.

Und morgen freuen wir uns über 14

Haben uns immerhin die 15 zurückerkämpft 😄

Hab jetzt meinen EK bei 16,40. Mal sehen was kommt 😂

😂👍

Ich öffne die App und sehe bico mal wieder um die 4% im Minus. Alles normal also

Wieder mal echt einstiegskurse heute…🤪

Wenigstens wieder die 16 zurückerobert, so traurig es auch klingt 😅

Ich glaube diese brutalen Schwankungen zeigen die kommenden Tage bis zum 23.02 haha

CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies. CollPlant and CELLINK will explore the use of CELLINK's next-generation high throughput extrusion bioprinters for the future commercial production of CollPlant's regenerative breast implants, addressing a $2.8 Bn market Today, CELLINK, a BICO Group company (Nasdaq Stockholm:BICO) and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies (Nasdaq:CLGN) a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced they have signed a collaboration agreement. Under this collaboration, CELLINK’s high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant's 3D bioprinted regenerative breast implants, addressing a current market size of $2.8 billion, with 2.2 million procedures performed annually worldwide. CollPlant has successfully produced prototypes of 3D bioprinted implants designed to regenerate breast tissue, and is currently evaluating these implants in a series of preclinical studies. Comprised of CollPlant’s rhCollagen and other biological components, the regenerative implants aim to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer. In contrast with current approaches, CollPlant’s regenerative implants are designed to degrade over time to be replaced by new, naturally grown breast tissue. CELLINK, a global leader in bioprinting, is well positioned to support CollPlant’s in their large-scale bioprinting production process through the use of its printers and technical expertise, addressing biofabrication challenges. “We are thrilled to be working with a partner who shares our values and passion to create the future of health. We look forward to making an impact in the breast implant industry but also to develop a long-lasting relationship with CollPlant characterized by advancements in the wider field of tissue engineering and regenerative medicine” said Cecilia Edebo, CEO CELLINK. “We are very pleased to enter into the collaboration with CELLINK, a recognized leader in development of 3D bioprinting solutions for the life-science industry,” said CollPlant's CEO, Yehiel Tal. “We believe CELLINK's high throughput bioprinters and biofabrication expertise will help us move toward the successful commercialization of our technology and to deliver a much-needed solution to patients around the world”.

Der 23. Wird die Richtung vorgeben

Oder vielleicht heute noch. Abwarten…

Und morgen -6%?!